Contributions
Abstract: EP1491
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - 15 Immunology
Background: Experimental and clinical studies have demonstrated immunomodulatory effect of vitamin D on the risk of developing experimental allergic encephalomyelitis (EAE), multiple sclerosis (MS) and correlation with the neurological deficit. Disputable questions are: vitamin D serum concentration necessary to suppress the immune response; subgroup of MS patients suitable for vitamin D treatment; optimal effective balance between and safe dosage of vitamin D.
Objective: To evaluate changes in serum concentration of 25(OH)D, IL4, IL10, TGFB1, IL17A, IFN-gamma,TNF-alpha in MS relapse and remission, and their correlation with patients' degree of disability.
Methods: A prospective, case-control study comprised 86 persons (18-50 years age) from Caucasians community dwelling at 41.5-42 northern latitude, who were registered during the astronomical winter period (October-May). Within these: 46 patients with relapsing-remitting MS (RRMS) according to McDonald criteria(2010),mean age 37±1.83 years, mean disease duration 7.17 ±1.17 years, Expanded Disability Status Scale (EDSS) score 1.5-5.0; 40 healthy controls matching by age and gender. Serum 25(OH)D and cytokine concentrations were measured by ELISA. Statistical methods: alternative, variance analysis, nonparametric test, correlation analysis and multiple linear regression analysis.
Results: RRMS patients had considerably lower serum levels of 25(OH)D than the healthy controls (p=0.09); 25(OH)D concentrations within the deficiency range for Bulgarian population (≤ 25nmol/l) were detected in 71.7% of the patients during relapse; serum 25(OH)D was significantly higher in clinical remission than in relapse phase (p=0.024). A significant negative correlation was found between 25(OH)D levels and EDSS in relapse (r= -0.416, p=0.004); 25(OH)D deficiency increased the risk of MS 3.43 times.
Significantly higher IL4, TGFβ1 and lower IFN-gamma levels were found in remission compared to relapse (p=0.006, p=0.009p=0.017).
Multiple Linear Regression Analysis established 25(OH)D, TNFalpha, IL17A as significant, independents factors determining EDSS score in relapse.
Conclusion: Our study showed a protective effect of 25(OH)D on the neurological deficit and the risk of developing the disease in Bulgarian patients with RRMS. Thus further studies are necessary to elucidate the therapeutic potential of 25(OH)D to modify the disease course.
Disclosure:
- Georgi S. Slavov-nothing to disclose
- Anastasiya G. Trenova-nothing to disclose
- Maria G. Manova-nothing to disclose
- Ivanka I. Kostadinova-nothing to disclose
- Zahari I. Zahariev-nothing to disclose
Abstract: EP1491
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - 15 Immunology
Background: Experimental and clinical studies have demonstrated immunomodulatory effect of vitamin D on the risk of developing experimental allergic encephalomyelitis (EAE), multiple sclerosis (MS) and correlation with the neurological deficit. Disputable questions are: vitamin D serum concentration necessary to suppress the immune response; subgroup of MS patients suitable for vitamin D treatment; optimal effective balance between and safe dosage of vitamin D.
Objective: To evaluate changes in serum concentration of 25(OH)D, IL4, IL10, TGFB1, IL17A, IFN-gamma,TNF-alpha in MS relapse and remission, and their correlation with patients' degree of disability.
Methods: A prospective, case-control study comprised 86 persons (18-50 years age) from Caucasians community dwelling at 41.5-42 northern latitude, who were registered during the astronomical winter period (October-May). Within these: 46 patients with relapsing-remitting MS (RRMS) according to McDonald criteria(2010),mean age 37±1.83 years, mean disease duration 7.17 ±1.17 years, Expanded Disability Status Scale (EDSS) score 1.5-5.0; 40 healthy controls matching by age and gender. Serum 25(OH)D and cytokine concentrations were measured by ELISA. Statistical methods: alternative, variance analysis, nonparametric test, correlation analysis and multiple linear regression analysis.
Results: RRMS patients had considerably lower serum levels of 25(OH)D than the healthy controls (p=0.09); 25(OH)D concentrations within the deficiency range for Bulgarian population (≤ 25nmol/l) were detected in 71.7% of the patients during relapse; serum 25(OH)D was significantly higher in clinical remission than in relapse phase (p=0.024). A significant negative correlation was found between 25(OH)D levels and EDSS in relapse (r= -0.416, p=0.004); 25(OH)D deficiency increased the risk of MS 3.43 times.
Significantly higher IL4, TGFβ1 and lower IFN-gamma levels were found in remission compared to relapse (p=0.006, p=0.009p=0.017).
Multiple Linear Regression Analysis established 25(OH)D, TNFalpha, IL17A as significant, independents factors determining EDSS score in relapse.
Conclusion: Our study showed a protective effect of 25(OH)D on the neurological deficit and the risk of developing the disease in Bulgarian patients with RRMS. Thus further studies are necessary to elucidate the therapeutic potential of 25(OH)D to modify the disease course.
Disclosure:
- Georgi S. Slavov-nothing to disclose
- Anastasiya G. Trenova-nothing to disclose
- Maria G. Manova-nothing to disclose
- Ivanka I. Kostadinova-nothing to disclose
- Zahari I. Zahariev-nothing to disclose